Report - IABP-SHOCK II-Studie: Interimsanalysendgk.org/daten/AG3_HT2011_Thiele.pdf · SOAP II (CS Subgruppe) In-hospital 15/40 13/40 1.15 (0.59;2.27) Up-stream Abciximab besser Standard-Behandlung

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form